Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181865 | 0.81 | KMT2A (0.51) | TDP1KMT2ASLC6A2SLC6A3MMP2 | |
| SCHEMBL20175317 | 0.78 | TDP1 (0.47) | TDP1KMT2ASLC6A2SLC6A3MMP2 | |
| SCHEMBL20173265 | 0.77 | MMP2 (0.51) | TDP1KMT2ASLC6A2SLC6A3MMP2 | |
| SCHEMBL20173262 | 0.77 | KMT2A (0.46) | TDP1KMT2ASLC6A2SLC6A3MMP2 | |
| SCHEMBL22272841 | 0.72 | RAB9A (0.49) | KMT2AALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL20181862 | 0.71 | KMT2A (0.50) | TDP1KMT2ASLC6A2SLC6A3MMP2 | |
| SCHEMBL15956900 | 0.71 | SMN1; SMN2 (0.52) | TDP1KMT2AALDH1A1LMNARAB9A | |
| SCHEMBL11301470 | 0.71 | TDP1 (0.53) | TDP1KMT2ASLC6A2SLC6A3MMP2 | |
| SCHEMBL21538018 | 0.70 | TDP1 (0.66) | TDP1KMT2ASLC6A2SLC6A3MMP2 | |
| SCHEMBL21350548 | 0.69 | TDP1 (0.47) | TDP1KMT2ASLC6A2SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | TDP1 719/4885KMT2A 4318/4885SLC6A2 4408/4885 |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | TDP1 719/4885KMT2A 4318/4885SLC6A2 4408/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | TDP1 719/4885KMT2A 4318/4885SLC6A2 4408/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | TDP1 672/4885KMT2A 4332/4885SLC6A2 4492/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | TDP1 672/4885KMT2A 4332/4885SLC6A2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.